While the results presented in this study firmly support CD36 as a critical receptor mediating the deleterious effects of Tr-OxPLs on lung endothelium, one important question remains unanswered: how do CD36 inhibitors protect against Tr-OxPLs-induced endothelial dysfunction? The gene discussed is CD36; the disease is endothelial dysfunction.